ADVERTISEMENT

GP IIb/IIIa Inhibitors

Yale-New Haven Health System Designates Tirofiban as the Primary Glycoprotein IIb/IIIa Inhibitor

04/26/2017

Samuel S. Hahn , MD, FACC, FSCAI;

Ralph J. Riello III, PharmD, BCPS;

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic...

04/26/2017

Cath Lab Digest

Challenges

A Case-Based Discussion of No-Reflow Treatment: Do We Need More?

04/05/2016

Cindy L. Grines , MD, FACC, FSCAI;

Amir Kaki , MD, FACC, FSCAI;

Herein, we present a case-based approach in order to discuss the available treatment of NR and to review the clinical significance of ventricular unloading.

Herein, we present a case-based approach in order to discuss the available treatment of NR and to review the clinical significance of ventricular unloading.

Herein, we present a case-based...

04/05/2016

Cath Lab Digest

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

Dermatology Week

November 13 ⁠–⁠ November 16

Derm Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

See Full Calendar

Advertisement

Advertisement